{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:56:40Z","timestamp":1791205000962,"version":"4.1.0"},"reference-count":147,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Breast cancer immunotherapy has advanced substantially, yet durable clinical benefit remains limited to selected patient populations, reflecting heterogeneity in tumor\u2013immune interactions across molecular subtypes, disease stages, and treatment contexts. This review frames immune responsiveness as a dynamic manifestation of tumor microenvironmental plasticity rather than a fixed tumor phenotype. We integrate mechanistic evidence showing that anti-tumor immunity is governed by interactions among malignant cells, immune populations, and cancer-associated fibroblasts. We emphasize therapeutic timing where treatment-induced changes in antigen availability, immune priming, stromal architecture, and cellular composition may create transient windows of immune susceptibility. Mechanisms of immune escape, including defective antigen presentation, T-cell dysfunction, suppressive myeloid populations, stromal exclusion, vascular abnormalities, and metabolic constraints, are evaluated as potential therapeutic targets. Emerging approaches incorporating single-cell and spatial profiling, circulating tumor DNA, multiomics, digital pathology, and artificial intelligence offer approaches for longitudinal characterization of evolving immune states, but their clinical utility in guiding immunotherapy remains largely unvalidated. We propose a precision-immunotherapy framework in which treatment selection and sequencing could be informed by these states. This framework complements established treatment approaches and defines testable hypotheses for prospective clinical studies.<\/jats:p>","DOI":"10.3390\/ijms27198854","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:31:31Z","timestamp":1791203491000},"page":"8854","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3196-2803","authenticated-orcid":false,"given":"S. M. Nashir","family":"Udden","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9187, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monira","family":"Obaid","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Texas at Dallas, Richardson, TX 75080-3021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-8020","authenticated-orcid":false,"given":"Laurentiu M.","family":"Pop","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9187, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9187, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast Cancer Immunotherapy: Facts and Hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","article-title":"A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer","volume":"177","author":"Wagner","year":"2019","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: Mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41592-021-01203-6","article-title":"Spatial omics and multiplexed imaging to explore cancer biology","volume":"18","author":"Lewis","year":"2021","journal-title":"Nat. Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mallardo, D., Ottaviano, M., Palmieri, G., and Melucci, M.T. (2026). Editorial: Immune-related biomarkers in skin and breast cancer: Innovations in immunological diagnostics and therapies. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1901169"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1586\/era.12.147","article-title":"Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade","volume":"12","year":"2012","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: Final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Mittendorf","year":"2025","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO-25-02311","article-title":"Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial","volume":"44","author":"Loibl","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: A randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: A randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.annonc.2025.08.005","article-title":"A-BRAVE trial: A phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients","volume":"36","author":"Conte","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Yizhak","year":"2018","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41523-026-00917-0","article-title":"The landscape of B and plasma cells in breast cancer: Insights from single-cell and spatial transcriptomics","volume":"12","author":"Cai","year":"2026","journal-title":"npj Breast Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer\u2013natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1038\/s41598-025-89882-5","article-title":"Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy","volume":"15","author":"Ciavattone","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","article-title":"Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing","volume":"9","author":"Bartoschek","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lee, H.H., and Al-Ogaili, Z. (2025). Fibroblast activation protein and the tumour microenvironment: Challenges and therapeutic opportunities. Oncol. Rev., 19.","DOI":"10.3389\/or.2025.1617487"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","article-title":"Metabolic Instruction of Immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Loi","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: A synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer","volume":"15","author":"Bianchini","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): A single-arm, multicentre, phase 1b\u20132 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab With Neoadjuvant Anti\u2013Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2\u2013Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial","volume":"40","author":"Huober","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"OT1-02-04","DOI":"10.1158\/1538-7445.SABCS17-OT1-02-04","article-title":"Abstract OT1-02-04: SWOG S1418\/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy","volume":"78","author":"Pusztai","year":"2018","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_76","unstructured":"U.S. Food and Drug Administration (2026, September 27). FDA Approves Sacituzumab Govitecanhziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of Triple-Negative Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: Building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/path.5389","article-title":"Radiation-induced tissue damage and response","volume":"250","author":"McBride","year":"2020","journal-title":"J. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Alard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon\u2013Dependent Innate and Adaptive Immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20200042","DOI":"10.1259\/bjr.20200042","article-title":"The abscopal effect 67 years later: From a side story to center stage","volume":"93","author":"Demaria","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Rech","year":"2015","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_94","first-page":"331","article-title":"Stereotactic radiation therapy combined with immunotherapy: Augmenting the role of radiation in local and systemic treatment","volume":"29","author":"Sharabi","year":"2015","journal-title":"Oncology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41523-025-00796-x","article-title":"The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer","volume":"11","author":"Fenton","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41523-025-00801-3","article-title":"Radiation therapy as a biological modifier of the breast cancer immune microenvironment","volume":"11","author":"Galluzzi","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: The TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1038\/s12276-024-01336-6","article-title":"VISTA-mediated immune evasion in cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41523-024-00704-9","article-title":"Immunotherapy for hormone receptor\u2013Positive HER2-negative breast cancer","volume":"10","author":"Cardoso","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: Phase 1b study","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1-or BRCA2 -Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","article-title":"Current and future immunotherapy for breast cancer","volume":"17","author":"Heater","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: Long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.annonc.2026.05.693","article-title":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: Results from arms 7 and 8 of the phase Ib\/II BEGONIA study","volume":"37","author":"Schmid","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17588359251327992","article-title":"TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"17","author":"Schmid","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): A randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.chembiol.2025.04.001","article-title":"Impact of radiation therapy on the immunological tumor microenvironment","volume":"32","author":"Guilbaud","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.ijrobp.2026.01.013","article-title":"Immuno-radiobiology: Effects of Radiation Therapy on Immune Cells, Tumor Microenvironment, Susceptibility of Tumor Cells to Immune-mediated Destruction, and Antitumor Immunity","volume":"125","author":"Wang","year":"2026","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kraja, F.P., Jurisic, V.B., Hromi\u0107-Jahjefendi\u0107, A., Rossopoulou, N., Katsila, T., Martinovic, K.M., Rivas, J.D.L., Diaconu, C.C., and Sz\u00f6\u0151r, \u00c1. (2025). Tumor-infiltrating lymphocytes in cancer immunotherapy: From chemotactic recruitment to translational modeling. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1601773"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"ref_138","first-page":"302ra133","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41467-025-56658-4","article-title":"Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay","volume":"16","author":"Elliott","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1038\/s41467-025-65432-5","article-title":"Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors","volume":"16","author":"Magbanua","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"106067","DOI":"10.1016\/j.esmoop.2026.106067","article-title":"Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer","volume":"11","author":"Grinshpun","year":"2026","journal-title":"ESMO Open"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology\u2014New tools for diagnosis and precision oncology","volume":"16","author":"Bera","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41591-018-0316-z","article-title":"A guide to deep learning in healthcare","volume":"25","author":"Esteva","year":"2019","journal-title":"Nat. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s41591-019-0462-y","article-title":"Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer","volume":"25","author":"Kather","year":"2019","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e71132","DOI":"10.1002\/cam4.71132","article-title":"Artificial Intelligence-Based Pathology to Assist Prediction of Neoadjuvant Therapy Responses for Breast Cancer","volume":"14","author":"Ji","year":"2025","journal-title":"Cancer Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-025-00873-1","article-title":"Biomarker prediction of immunotherapy response in breast cancer: From single markers to multi-omics integration","volume":"12","author":"Moghaddam","year":"2025","journal-title":"npj Breast Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8854\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:35:03Z","timestamp":1791203703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":147,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198854"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198854","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]}}}